Abbott to acquire Cerevel and its neuroscience pipeline
tengxiao
发表于 2023-12-7 19:50:30
3676
0
0
On December 7th, Abbey and Cerevel Therapeutics announced a final agreement - Abbey will acquire Cerevel Therapeutics and its neuroscience pipeline. Cerevel's pipeline consists of multiple clinical stages and preclinical candidate drugs developed to treat diseases such as schizophrenia, Parkinson's disease (PD), and mood disorders.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Tianjing Biotechnology management welcomes another 'major overhaul': the shadow of CD47 target failure still lingers in the innovation pipeline with only three remaining CD47 targets
- Huang Renxun: AI is sparking a scientific revolution, and the era of robots is coming
- Bristol Myers Squibb regains exclusive development and commercialization rights for RayzeBio pipeline products in the Greater China market
